Brain-Included 18F FDG PET/CT Acquisition Protocol: Cancer-Specified Clinical Impact of Newly-Diagnosed Brain Metastasis in Extra-Cerebral Cancer Patients

Mehrdad Bakhshayeshkaram, Fahimeh Tavakoli, Maryam Hassanzad, Sharareh Seifi, Hamid Reza Jamaati, farahnaz Aghahosseini

26

Abstract

Background: Evolution of individualized radiosurgical therapeutic methods for brain metastasis as an ominous prognostic finding may encourage a more extensive application of neuroimaging in patients with extracerebral cancer. The aim of the present study was to investigate the added value of brain-included 18 F FDG PET/CT acquisition protocol based on primary cancer type and clinical indication.

Materials and Methods: A retrospective review was performed on 3945 18 F FDG PET/CT reports of patients with extra-cerebral cancer underwent brain-included PET/CT study. Cerebral lesions suggestive of brain metastasis were subsequently verified by MRI, MRI+MRS, surgical pathology and a 1-year clinical formal follow up. The detection rate of new brain metastasis and related impact on disease status were then investigated in each cancer type based on clinical indication.

Results: Of a total 3933 eligible patients, 44 (1.12%) were finally verified to have new cerebral metastasis. The most common primary sources were lung cancer (19/385, 4.93%), cancer of unknown primary (CUP) (5/168, 2.97%) and breast cancer (8/468, 1.71%). The most common clinical indications were initial staging (17/44, 43.1%) and restaging (19/44, 36.4%). Change in disease status occurred in 12 out of 44 patients (27.3%), more frequently occurred in lung cancer (n=4), in all indications and breast (n=3) cancers at restaging (n=7, 43.8%).

Conclusion: PET/CT acquisition protocol study may be best optimized based on the type of primary cancer and timing of evaluation. Brain-included field of view may be recommended for lung cancer regardless the clinical indication, cancer of unknown primary and breast cancer at restaging.

Keywords

Brain Metastasis, brain-included 18F FDG PET/CT, Clinical Indication, Cancer Type, Change Status

Full Text:

PDF

References

Gavrilovic IT, Posner JB. Brain metastases: epidemiology and pathophysiology. Journal of neuro-oncology. 2005;75(1):5-14.

Schouten LJ, Rutten J, Huveneers HA, Twijnstra A. Incidence of brain metastases in a cohort of patients with carcinoma of the breast, colon, kidney, and lung and melanoma. Cancer. 2002;94(10):2698-705.

Ludwig V, Komori T, Kolb D, Martin WH, Sandler MP, Delbeke D. Cerebral lesions incidentally detected on 2-deoxy-2-[18 F] fluoro-D-glucose positron emission tomography images of patients evaluated for body malignancies. Molecular Imaging & Biology. 2002;4(5):359-62.

Rohren EM, Provenzale JM, Barboriak DP, Coleman RE. Screening for Cerebral Metastases with FDG PET in Patients Undergoing Whole-Body Staging of Non–Central Nervous System Malignancy 1. Radiology. 2003;226(1):181-7.

Tasdemir B, Dostbil Z, Inal A, Unal K, Yildirim S, Simsek FS. Evaluation of clinical contributions provided by addition of the brain, calvarium, and scalp to the limited whole body imaging area in FDG-PET/CT tumor imaging. BioMed research international. 2014;2014.

Abdelmalik AG, Alenzi S, Muzaffar R, Osman MM. The Incremental Added Value of Including the Head in 18F-FDG PET/CT Imaging for Cancer Patients. Frontiers in oncology. 2013;3:71.

Bochev P, Klisarova A, Kaprelyan A, Chaushev B, Dancheva Z. Brain metastases detectability of routine whole body (18) F-FDG PET and low dose CT scanning in 2502 asymptomatic patients with solid extracranial tumors. Hellenic journal of nuclear medicine. 2011;15(2):125-9.

Hendriks LE, Bootsma GP, de Ruysscher DK, Scheppers NA, Hofman PA, Brans BT, Dingemans AM. Screening for brain metastases in patients with stage III non-small cell lung cancer: Is there additive value of magnetic resonance imaging above a contrast-enhanced computed tomography of the brain?. Lung Cancer. 2013;80(3):293-7.

Osman MM, Chaar BT, Muzaffar R, Oliver D, Reimers HJ, Walz B, et al. 18F-FDG PET/CT of patients with cancer: comparison of whole-body and limited whole-body technique. American Journal of Roentgenology. 2010;195(6):1397-403.

Lee HY, Lee KS, Kim BT, Cho YS, Lee EJ, Yi CA, et al. Diagnostic efficacy of PET/CT plus brain MR imaging for detection of extrathoracic metastases in patients with lung adenocarcinoma. Journal of Korean medical science. 2009;24(6):1132-8.

Sebro R, Mari-Aparici C, Hernandez-Pampaloni M. Value of true whole-body FDG-PET/CT scanning protocol in oncology: optimization of its use based on primary diagnosis. Acta Radiologica. 2013;54(5):534-9.

Gavrilovic IT, Posner JB. Brain metastases: epidemiology and pathophysiology. Journal of neuro-oncology. 2005;75(1):5-14.

Schouten LJ, Rutten J, Huveneers HA, Twijnstra A. Incidence of brain metastases in a cohort of patients with carcinoma of the breast, colon, kidney, and lung and melanoma. Cancer. 2002;94(10):2698-705.

Clayton AJ, Danson S, Jolly S, Ryder WD, Burt PA, Stewart AL, Wilkinson PM, Welch RS, Magee B, Wilson G, Howell A. Incidence of cerebral metastases in patients treated with trastuzumab for metastatic breast cancer. British journal of cancer. 2004;91(4):639.

Bakhshayeshkaram M, Ghobadi M, Hassanzad M, Doroudinia A, Jamaati H, Aghahosseini F. Diagnostic performance of F-18 FDG PET/CT in patients with cancer of unknown primary: additional benefit over CT-based conventional work up. Novelty in Biomedicine. 2016;4(1):5-12.

Rudà R, Borgognone M, Benech F, Vasario E, Soffietti R. Brain metastases from unknown primary tumour. Journal of neurology. 2001;248(5):394-8.

Pavlidis N, Khaled H, Gaafar R. A mini review on cancer of unknown primary site: a clinical puzzle for the oncologists. Journal of advanced research. 2015;6(3):375-82.